Company Profile
BioMarin Pharmaceutical Stock Price, News & Catalysts
- Ticker:
- BMRN
- Exchange:
- NASDAQ
- Sector:
- Gene Therapy
- Location:
- San Rafael, California
Stock performance
56.22 USD (-2.29%)
Close
Last updated: October 6, 2026
10.3B USD
Market cap
Why the stock is moving
As of Oct 6, 2026, BMRN closed down 2.29% at $56.22. No new same-company headline was identified in the current news window.
Company overview
Global Rare-Disease Biotechnology Company
BioMarin develops and commercializes medicines for genetically defined rare diseases. Its model combines genetic and disease-biology expertise with biologics, small molecules, enzyme replacement, peptide therapeutics, and gene therapy, supported by a global commercial and manufacturing organization.
Skeletal Conditions Franchise
VOXZOGO is the center of BioMarin's skeletal-conditions business and is approved for children with achondroplasia. The company is expanding the franchise into hypochondroplasia while developing BMN 333, a long-acting C-type natriuretic peptide intended to support less frequent dosing in achondroplasia.
Metabolic and Enzyme-Therapy Portfolio
BioMarin markets VIMIZIM, NAGLAZYME, PALYNZIQ, BRINEURA, and ALDURAZYME across inherited metabolic and neurological disorders. The acquisition of Amicus added GALAFOLD for Fabry disease and POMBILITI plus OPFOLDA for late-onset Pompe disease, broadening the commercial portfolio across oral and enzyme-based treatment modalities.
Gene Therapy and Genetic Medicines
The company developed ROCTAVIAN for hemophilia A and retains gene-therapy capabilities even as it narrows commercial focus. Its pipeline also includes BMN 351 for Duchenne muscular dystrophy and collaborations involving antisense oligonucleotides for rare neurodevelopmental conditions.
Pipeline Expansion Through Business Development
BioMarin supplements internal research with targeted acquisitions and licenses. BMN 820, an oral CCR2 inhibitor for focal segmental glomerulosclerosis, adds a late-stage kidney-disease program, while the Amicus transaction increased both the number of marketed therapies and the company's addressable rare-disease population.
Future catalysts
- Presentation of the full Phase 3 CANOPY-HCH-3 dataset for VOXZOGO in hypochondroplasia at the European Society for Paediatric Endocrinology meeting in September 2026.
- Update on FDA review status of the VOXZOGO hypochondroplasia sNDA with third-quarter 2026 results, followed by a potential 2027 launch if approved.
- FDA PDUFA decision on full approval of VOXZOGO in children with achondroplasia on February 28, 2027.
- Phase 2/3 data update for long-acting CNP candidate BMN 333 in 2027.
- Pivotal Phase 3 ACTION 3 data for BMN 820 in focal segmental glomerulosclerosis in 2028.
- BMN 351 Duchenne muscular dystrophy program update by year-end 2026.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of BioMarin Pharmaceutical (BMRN)?
BioMarin Pharmaceutical (BMRN) most recently closed at 56.22 USD, a -2.29% move versus the previous session.
What is the market cap of BioMarin Pharmaceutical (BMRN)?
BioMarin Pharmaceutical currently has a market capitalization of 10.3B USD on BioPharmSignal.
What does BioMarin Pharmaceutical do?
Global Rare-Disease Biotechnology Company BioMarin develops and commercializes medicines for genetically defined rare diseases. Its model combines genetic and disease-biology expertise with biologics, small molecules, enzyme replacement, peptide therapeutics, and gene therapy, supported by a global commercial and manufacturing organization. Skeletal...
On which exchange is BMRN stock listed?
BioMarin Pharmaceutical (BMRN) is associated with NASDAQ, San Rafael, California, Gene Therapy.
What is CANOPY-HCH-3?
Presentation of the full Phase 3 CANOPY-HCH-3 dataset for VOXZOGO in hypochondroplasia at the European Society for Paediatric Endocrinology meeting in September 2026.
Which conditions is BioMarin Pharmaceutical targeting with CANOPY-HCH-3?
BioMarin Pharmaceutical is associated with rare disease, metabolic disease, genetic disease based on its company overview and current catalyst commentary.
How does BioMarin Pharmaceutical describe recent progress with CANOPY-HCH-3?
Presentation of the full Phase 3 CANOPY-HCH-3 dataset for VOXZOGO in hypochondroplasia at the European Society for Paediatric Endocrinology meeting in September 2026.
What is Global?
Global Rare-Disease Biotechnology Company BioMarin develops and commercializes medicines for genetically defined rare diseases.